INDIANAPOLIS and SAN DIEGO, Oct. 7,
2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for
U.S. healthcare providers (HCPs) about Lilly's new rapid-acting
mealtime insulin Lyumjev™ (insulin lispro-aabc
injection, 100 units/mL and 200 units/mL), now available in U.S.
pharmacies, and Dexcom G6 CGM Systems. The program is designed to
help clinicians use data to inform diabetes management, including
giving visibility to the benefits of a new mealtime insulin.
HCPs treating type 1 and type 2 diabetes will be able to assess
their patients' glucose levels and time in range with Dexcom G6 or
Dexcom G6 Pro, either in blinded or unblinded mode, helping them
quickly identify adult patients who struggle to manage their
postprandial glucose (PPG) levels (glucose levels following meals)
and who may benefit from a treatment like Lyumjev. As PPG is often
overlooked as a significant contributor to A1C,1 this
partnership also aims to elevate PPG monitoring as an important
component of diabetes treatment management.
"When it comes to treating diabetes, our partnership with Dexcom
has the potential to be meaningful for HCPs who want to help their
patients who may be struggling to manage their blood glucose levels
after meals," said Adrienne Brown,
vice president, U.S. Diabetes and Connected Care, Lilly. "Through
this program, we can inspire confidence as clinicians and their
patients evaluate new treatment options by showcasing how using
these resources together can inform diabetes care."
Lilly and Dexcom will enhance HCP education by jointly sharing
information about Lyumjev and the Dexcom G6 and G6 Pro through a
variety of channels.
"We are thrilled to partner once again with a leader in diabetes
care like Lilly," said Rick
Doubleday, chief commercial officer at Dexcom. "Our goal is
that the real-time data provided through Dexcom G6 and Dexcom G6
Pro will allow healthcare providers to help their patients with
diabetes make more informed decisions, measure and evaluate their
time in range, and have more visibility to the potential benefits
of transitioning to a new mealtime insulin such as Lyumjev."
Those interested in learning more about Dexcom CGM or getting
started on the Dexcom G6 should visit Dexcom.com. The Dexcom G6 is
covered by 98 percent of private insurance in the U.S., by Medicare
and by Medicaid in many states across the country. Dexcom also
recently launched a patient assistance program available to
current U.S. customers who lost their health insurance coverage due
to the impacts of COVID-19.
Lyumjev is a novel formulation of insulin lispro, developed to
speed the absorption of insulin into the bloodstream and reduce A1C
levels in adults with diabetes. In clinical studies, Lyumjev
provided superior reduction in blood sugar spikes compared with
Humalog® (insulin lispro injection) when blood sugar was
measured 1 and 2 hours after a meal. Lyumjev was approved by the
FDA on June 15, 2020. HCPs can now
prescribe Lyumjev, which is available for pharmacies nationwide to
order. People who have commercial insurance can visit
www.Lyumjev.com to access the Lyumjev Savings Card. For people
without insurance coverage, Lyumjev is also included in the Lilly
Insulin Value Program for $35 by
calling the Lilly Diabetes Solution Center at (833) 808-1234.
Operators at the Solution Center are available Monday through
Friday from 8 a.m. to 8 p.m. (ET).
Lilly is in discussions with insurance providers to make the new
rapid-acting insulin available to as many people as possible.
People with diabetes and their HCPs who have questions about
Lyumjev can visit www.Lyumjev.com or call The Lilly Answers Center
at 1-800-LillyRx (1-800-545-5979), Monday through Friday from
9 a.m. to 8 p.m. ET.
Terms, conditions, and limitations apply to Lilly savings cards
and the Dexcom patient assistance program. See the companies'
respective websites for additional details. The Lilly savings card
is not available to those patients with government insurance such
as Medicaid, Medicare, Medicare Part D,
TRICARE®/CHAMPUS, Medigap, DoD, or any State Patient or
Pharmaceutical Assistance Program. TRICARE® is a
registered trademark of the Department of Defense (DoD), DHA.
PURPOSE and SAFETY SUMMARY
Important Facts About LYUMJEV™ (LOOM-jehv) and
Humalog® (HU-ma-log)
- Lyumjev is also known as insulin lispro-aabc injection. Humalog
is also known as insulin lispro injection.
- Lyumjev is a fast-acting insulin. Lyumjev is used to control
high blood sugar in adults with diabetes. Humalog is a fast-acting
insulin. Humalog is used to control high blood sugar in adults and
children with diabetes. Lyumjev and Humalog are available only with
a prescription.
- Lyumjev comes in two strengths: U-100 (100 units per
milliliter) and U-200 (200 units per milliliter). The Lyumjev U-200
prefilled pen contains 2 times as much insulin per 1
milliliter as standard (U-100) insulin. Humalog U-100 contains 100
units of insulin per milliliter. The dose window of the pen shows
the number of insulin units to be delivered.
- It is not known if Lyumjev is safe and effective for children.
It is not known if Humalog is safe and effective for children with
type 2 diabetes or for children younger than 3 years of age with
type 1 diabetes as there were no studies done with Humalog in these
groups of children. If your doctor decides to give your child any
insulin products, he or she may give you special instructions.
All Lyumjev and Humalog products contain insulin lispro.
Warnings
Do not take Lyumjev or Humalog if you have:
- symptoms of low blood sugar (hypoglycemia)
- an allergy to Lyumjev or Humalog or any of their
ingredients.
Do not reuse needles or share your insulin injection supplies
with other people. This includes your:
- prefilled pen for use by a single patient
- cartridges
- reusable pen that works with Lilly 3mL cartridges available for
Humalog
- needles
- syringes
You or the other person can get a serious infection. This can
happen even if you change the needle.
Do not change the type of insulin you take or your
dose, unless your doctor tells you to. This could cause low or high
blood sugar, which could be serious.
Do not use a syringe to remove Lyumjev or Humalog
from your prefilled pen. This can cause you to take too much
insulin. Taking too much insulin can lead to severe low blood
sugar. This may result in seizures or death.
Lyumjev and Humalog may cause serious side effects. Some of
these can lead to death. The possible serious side effects
are:
- Low blood sugar. This can cause:
•
dizziness or lightheadedness
|
•
sweating
|
•
confusion
|
•
headache
|
•
blurred vision
|
•
slurred speech
|
•
shakiness
|
•
fast heartbeat
|
•
anxiety
|
•
irritability
|
•
mood change
|
•
hunger
|
If you are at risk of having severely low blood sugar, your
doctor may prescribe a glucagon emergency kit. These are used when
your blood sugar becomes too low and you are unable to take sugar
by mouth. Glucagon helps your body release sugar into your
bloodstream.
- Severe allergic reaction.
Get emergency help right
away if you have:
• a
rash over your whole body
|
•
trouble breathing
|
• a
fast heartbeat
|
•
sweating
|
• a
faint feeling
|
•
shortness of breath
|
•
extreme drowsiness
|
•
dizziness
|
•
confusion
|
•
swelling of your face, tongue,
or throat
|
- Low potassium in your blood. This can lead to
severe breathing problems, irregular heartbeat, and death.
- Heart failure. Taking diabetes pills called
thiazolidinediones (thIE-uh-zOH-li-dEEn-dIE-OHns), or "TZDs," with
Lyumjev or Humalog may cause heart failure in some people. This
includes people who do not have any heart problems. If you have
heart failure, it may get worse if you take TZDs with Lyumjev or
Humalog. Tell your doctor if you have any new symptoms of heart
failure, or if they get worse. Some symptoms of heart failure
include: shortness of breath, swelling of ankles and feet, and
sudden weight gain. Your doctor may need to change or stop
treatment with TZDs and your insulin lispro product.
- High blood sugar and ketoacidosis for Humalog insulin pump
users. You can have these serious problems when your
insulin pump or infusion set stops working. They can also happen if
your insulin is no longer effective. For these reasons, always keep
extra insulin injection supplies with you.
Common side effects
The most common side effects of Lyumjev
and Humalog are:
•
low blood sugar
|
•
allergic reactions
|
•
reactions where you have injected insulin
|
•
skin thickening or pits at the injection
site
|
•
itching
• weight
gain
|
•
rash
|
Other most common side effects with Humalog include swelling of
your hands or feet.
These are not all of the possible side effects. Tell your
doctor if you have any side effects. You can report side effects at
1-800-FDA-1088 or www.fda.gov/medwatch.
Before using
Talk with your doctor about low blood sugar and how to manage
it. Also tell your doctor:
- about all of the medicines you take, including over-the-counter
medicines, vitamins, and herbal supplements.
- about any other prescription medicines you take, especially
ones called TZDs.
- about all of your medical conditions, including if you have
heart failure or other heart, liver, or kidney problems.
- if you are pregnant, breastfeeding, or plan to become pregnant
or breastfeed.
How to take
Read the Instructions for Use that come with your
Lyumjev or Humalog. Be sure to take your Lyumjev
or Humalog and check your blood sugar levels exactly as
your doctor tells you to. Your doctor may tell you to change your
dose because of illness, increased stress, or changes in your
weight, diet, or physical activity level. He or she may also tell
you to change the amount or time of your dose because of other
medicines or different types of insulin you take.
Before injecting your Lyumjev or Humalog
You can inject your insulin dose yourself, or you can have a
trained caregiver inject it for you. Make sure you or your
caregiver:
- Check the insulin label before each injection. This will help
you make sure that you are taking the correct insulin.
- Use a new needle for each injection. You can get a serious
infection or the wrong dose of insulin if you re-use needles.
- Change (rotate) where you inject your insulin with each dose.
This can reduce your chance of getting pits, lumps, or thickened
skin where you inject your insulin. Do not inject your
insulin into the exact same spot or where the skin has pits or
lumps. Avoid injecting into thickened, tender, bruised,
scaly, hard, scarred, or damaged skin.
When you are ready to inject
- Inject Lyumjev under your skin at the beginning of a meal or
within 20 minutes after you start eating a meal.
- Inject Humalog under your skin within 15 minutes before or
right after you eat a meal.
Staying safe while taking your Lyumjev or Humalog
To stay safe while taking your insulin, be sure to never
inject Lyumjev U-200 in your vein, muscle, or with an insulin
pump. Also be sure not to:
- mix Lyumjev with other insulins
- drive or use heavy machinery until you know how your Lyumjev or
Humalog affects you.
- drink alcohol or use other medicines that contain alcohol when
taking your Lyumjev or Humalog.
Learn more
For more information, call 1-800-545-5979 or go to
www.Lyumjev.com or www.humalog.com
This summary provides basic information about
Lyumjev and Humalog. It does not include all information
known about these medicines. Read the information that comes with
your prescription each time your prescription is filled. This
information does not take the place of talking with your doctor. Be
sure to talk to your doctor or other health care provider about
your insulin lispro product and how to take it. Your doctor is the
best person to help you decide if these medicines are right for
you.
Please see Lyumjev Full Prescribing Information including
Patient Prescribing Information
Please see Humalog Full Prescribing Information including
Patient Prescribing Information
LyumjevTM is a trademark and Humalog® is a
registered trademark owned or licensed by Eli Lilly and
Company, its subsidiaries, or affiliates.
UR HI CON BS 15JUN2020
About Diabetes
Approximately 34 million Americans2 (just over 1 in
10) and an estimated 463 million adults worldwide3 have
diabetes. Type 2 diabetes is the most common type internationally,
accounting for an estimated 90 to 95 percent of all diabetes cases
in the United States
alone1. Diabetes is a chronic disease that occurs when
the body does not properly produce or use the hormone insulin.
About Dexcom CGM
The Dexcom G6 provides data-driven
insights that are designed to allow people with diabetes to improve
their insulin therapy and condition management. Dexcom G6
capabilities include continuous glucose readings, the elimination
of routine fingersticks,* proactive and predictive
alerts and alarms, remote glucose monitoring† and more.
The G6 Pro is also the first and only single use, professional CGM
available in blinded and unblinded mode that allows healthcare
providers to view data about a patient's glucose patterns over a
single 10-day period. Through Dexcom CLARITY – a diabetes
management application offered for both patients and physicians –
HCPs can access data remotely, regardless of whether their patients
are using the personal or professional version of G6.
About DexCom Inc.
DexCom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) products.
Headquartered in San Diego,
California, Dexcom has emerged as a leader of diabetes care
technology. By listening to the needs of patients, caregivers, and
clinicians, Dexcom simplifies and improves diabetes management
around the world.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when
we introduced the world's first commercial insulin. Today we are
building upon this heritage by working to meet the diverse needs of
people with diabetes and those who care for them. Through research,
collaboration and quality manufacturing we strive to make life
better for people affected by diabetes and related conditions. We
work to deliver breakthrough outcomes through innovative
solutions—from medicines and technologies to support programs and
more. For the latest updates, visit http://www.lillydiabetes.com/or
follow us on Twitter: @LillyDiabetes and Facebook:
LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring
with discovery to create medicines that make life better for people
around the world. We were founded more than a century ago by a man
committed to creating high-quality medicines that meet real needs,
and today we remain true to that mission in all our work. Across
the globe, Lilly employees work to discover and bring life-changing
medicines to those who need them, improve the understanding and
management of disease, and give back to communities through
philanthropy and volunteerism. To learn more about Lilly, please
visit us at lilly.com and lilly.com/newsroom.
P-LLY
*If your glucose alerts and readings from the G6 do not match
symptoms or expectations, use a blood glucose meter to make
diabetes treatment decisions.
†Separate Follow app required.
© 2020 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are
registered trademarks of Dexcom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about Lyumjev™ (insulin lispro-aabc
injection) as a treatment to improve glycemic control in adults
with type 1 and type 2 diabetes, and a joint program between Eli
Lilly and Company and DexCom, Inc. designed to help U.S. healthcare
providers use data to inform diabetes management and reflects
Lilly's current beliefs. However, as with any pharmaceutical
product or medical device, there are substantial risks and
uncertainties in the process of development and commercialization.
Among other things, there is no guarantee that Lyumjev will be
commercially successful or receive additional regulatory approvals.
For further discussion of these and other risks and uncertainties,
see Lilly's most recent Form 10-K and Form 10-Q filings with the
United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this release.
PP-UR-US-0211 10/2020 ©Lilly USA, LLC 2020. All rights reserved.
References
1. Hershon, K., Hirsh, B., and Odugbesan, O. Importance of
Postprandial Glucose in Relation to A1C and Cardiovascular Disease.
Clinical Diabetes. 2019; 37 (3): 250-269. Available at:
https://clinical.diabetesjournals.org/content/37/3/250.article-info
2. Centers for Disease Control and Prevention. National Diabetes
Statistics Report, 2020. Atlanta,
GA: Centers for Disease Control and Prevention, U.S. Dept.
of Health and Human Services; 2020.
3. International Diabetes Federation. IDF Diabetes Atlas, 9th edn.
Brussels, Belgium: International
Diabetes Federation, 2019. Available at:
http://diabetesatlas.org.
Refer to:
|
Maggie Pfeiffer;
monson_maggie@lilly.com; +1 (317) 650-5939 (Lilly Media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; +1 (317) 277-1838 (Lilly
Investors)
|
|
James McIntosh;
james.mcintosh@dexcom.com; +1 (619) 884-2118 (Dexcom
Media)
|
|
Steve Pacelli;
spacelli@dexcom.com; +1 (858) 200-0255 (Dexcom
Investors)
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-and-dexcom-team-up-on-new-program-to-help-improve-diabetes-management-301147221.html
SOURCE Eli Lilly and Company